Literature DB >> 16254201

What does it take to make the perfect clot?

Dougald M Monroe1, Maureane Hoffman.   

Abstract

The coagulation process has been conceptualized as being primarily dependent on adequate levels of the coagulation proteins. This concept was based on the clear relationship between the bleeding tendency and factor levels in hemophilia. The field is now evolving toward conceptualizing coagulation as being actively regulated by the specialized cellular components of the process. Rather than conceiving coagulation as only a "cascade" of proteolytic reactions, the coagulation reactions occur as overlapping steps on cell surfaces. Components of the old "extrinsic'" and "intrinsic" pathways of coagulation can be thought of as participating in the initiation and propagation of coagulation reactions, respectively. Thus, these pathways are not redundant as they are portrayed in the cascade model, but play distinct and complementary roles. Our understanding of how specific cellular features control the processes of hemostasis and thrombosis is developing rapidly. This review discusses some aspects of the cellular control of coagulation.

Entities:  

Mesh:

Year:  2005        PMID: 16254201     DOI: 10.1161/01.ATV.0000193624.28251.83

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  100 in total

1.  Understanding the delicate balance between bleeding and thrombosis: can we use it to our advantage?

Authors:  Filip De Somer
Journal:  J Extra Corpor Technol       Date:  2012-03

Review 2.  [New oral anticoagulants: better than vitamin K antagonists?].

Authors:  H Völler; S Alban; D Westermann
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

3.  NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition.

Authors:  Viviane S De Paula; Nikolaos G Sgourakis; Ivo M B Francischetti; Fabio C L Almeida; Robson Q Monteiro; Ana Paula Valente
Journal:  Blood       Date:  2019-05-27       Impact factor: 22.113

4.  Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow.

Authors:  Judith M E M Cosemans; Saskia E M Schols; Lucia Stefanini; Susanne de Witt; Marion A H Feijge; Karly Hamulyák; Hans Deckmyn; Wolfgang Bergmeier; Johan W M Heemskerk
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

5.  Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

Authors:  R Stagaard; M J Flick; B Bojko; K Goryński; P Z Goryńska; C D Ley; L H Olsen; T Knudsen
Journal:  J Thromb Haemost       Date:  2018-06-21       Impact factor: 5.824

6.  Deciphering the Roles of N-Glycans on Collagen-Platelet Interactions.

Authors:  Christian Toonstra; Yingwei Hu; Hui Zhang
Journal:  J Proteome Res       Date:  2019-05-15       Impact factor: 4.466

7.  Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.

Authors:  Frauke Swieringa; Marijke J E Kuijpers; Moniek M E Lamers; Paola E J van der Meijden; Johan W M Heemskerk
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

8.  Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex.

Authors:  Daniel J D Johnson; Jonathan Langdown; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Authors:  Rikke Stagaard; Carsten Dan Ley; Kasper Almholt; Lisbeth Høier Olsen; Tom Knudsen; Matthew J Flick
Journal:  Blood Adv       Date:  2018-11-27

10.  Thromboembolic complications in Fontan patients: population-based prevalence and exploration of the etiology.

Authors:  L Idorn; A S Jensen; K Juul; J I Reimers; P I Johansson; K E Sørensen; S R Ostrowski; L Søndergaard
Journal:  Pediatr Cardiol       Date:  2012-07-28       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.